News & Events

Pleased to share our new ENOTTA publication in Clinical and Translational Science: European Network on Optimizing Treatment With Therapeutic Antibodies in Chronic Inflammatory Diseases: Overview, Progress and Perspectives This article…

Thank you to everyone who joined us for the final ENOTTA COST Action meeting in Novara (June 10-12)! held at the beautiful Università degli Studi del Piemonte Orientale, it was…

We are proud to share a new study from our members Dr. Athan Baillet and Dr. Denis Mulleman, regarding the search for precision medicine in axial spondyloarthritis (axSpA). The Study: Serum…

We are pleased to share our latest research outcome from the STSM published in Psoriasis: Targets and Therapy (Dove Medical Press), identifying key genetic drivers in psoriasis lesions. 🧬 Summary:…

We are thrilled to announce the publication of our latest paper: “Statement on education and scientific research in the field of therapeutic drug monitoring by the COST Action ENOTTA CA21147.”…

Last week, the COST Action ENOTTA (CA21147) successfully hosted its Biomarker Training School at the University of Manchester, UK. Following opening remarks by Prof. Denis Mulleman, Action Chair, trainees from…

We are pleased to share a new publication from COST Action ENOTTA (CA21147) entitled:  “From reactive to predictive: Advancing biologic dosing in dermatology” Biologic therapies have transformed the management of…

The COST Action ENOTTA (CA21147) – 2nd International Conference and Management Committee Meeting was successfully held in Madrid, Spain, from 10–12 December 2025. The event brought together researchers, clinicians, and…

We are pleased to announce that our Working Group members have published a new paper in the jounal, Basic & Clinical Pharmacology & Toxicology entitled: “Quality Assessment of Therapeutic Drug…

📢 New Publication from the Members of ENOTTA in the British Journal of Clinical Pharmacology We are proud to announce that ENOTTA members have published the paper “Therapeutic drug monitoring…